首页> 外文期刊>European review for medical and pharmacological sciences. >Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization
【24h】

Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization

机译:帕洛诺司琼对心肌复极透壁分散的急性作用评估

获取原文
获取原文并翻译 | 示例
           

摘要

Background: 5-hydroxytrypta-mine receptor type-3 (5-HT_3) antagonists are widely used for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) and regarded to have a high safety profile. However, several electrocardiographic changes and cardiac arrhythmias have been reported due to administration of 5-HT_3 antagonists. Only prolongation of QT interval has been investigated as an index of potential for life-threatening arrhythmias in adult patients using 5-HT_3 antagonists. Recently, increase in transmural dispersion of repolarization (TDR) has been proposed as a more reliable determinant of arrhythmogenic potential.Aim: To assess the effects of palonosetron, a second-generation 5-HT_3 antagonist, on the T-wave peak to T-wave end (TpTe) interval which has been proposed as a reliable index of spatial TDR.Patients and Methods: A total of 50 consecutive cancer patients (aged: 57 +- 12 years) who were scheduled to receive emetogenic chemotherapy were included to the study. Baseline12-lead electrocardiography (ECG) recordings were obtained. Then, all patients received 8 mg intravenous dexamethasone followed by a single dose of 0.25 mg intravenous palonosetron administered over 30 seconds. A second ECG was performed 30 minutes after the administration of palonosetron. Indices of cardiac repolarization and TDR before and after the administration of palonosetron were compared.
机译:背景:5-羟色胺受体3型(5-HT_3)拮抗剂被广泛用于预防化疗引起的恶心和呕吐(CINV),并被认为具有很高的安全性。然而,由于施用5-HT_3拮抗剂,已经报道了一些心电图改变和心律不齐。仅使用QT间隔延长作为使用5-HT_3拮抗剂的成年患者危及生命的心律不齐的潜在指标。近年来,人们提出增加跨壁复极色散(TDR)作为心律失常潜力的更可靠的决定因素。目的:评估第二代5-HT_3拮抗剂帕洛诺司琼对T波峰产生的影响。病人和方法:总共50例计划接受致癌化疗的连续癌症患者(年龄:57±12岁)被纳入研究。 。获得基线12导联心电图(ECG)记录。然后,所有患者均接受8 mg地塞米松静脉注射,然后在30秒内给予单剂量0.25 mg帕洛诺司琼静脉注射。给予帕洛诺司琼后30分钟进行第二次ECG。比较了帕洛诺司琼给药前后的心脏复极和TDR指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号